Lumida
/LIVN
⌘K
LivaNova PLC

LivaNova PLC

LIVN
$80.70USD↓-1.33%-1.09 today

MARKET CAP

4.4B

P/E (TTM)

20.2x

FWD P/E

18.0x

DAY RANGE

$80 – $82

52W RANGE

$41
$85

AI Summary

Stalk
StalkMedium

While the long-term uptrend remains intact since mid-2025, a recent Support Failure and breach of the 9/21 EMA zone have triggered a corrective pullback within Stage 2. Price holds above the rising 50 DMA and 200 DMA, preserving the uptrend, but short-term momentum is unfavorable for new buys. Medium-term bias remains bullish, suggesting selective deferred entries on stabilization or reclaim of the EMA zone.

  • ↑Q1 revenue $362 M (+11% YoY) and adjusted EPS $0.98 beat $0.85 consensus.
  • ↑Full-year revenue guidance raised to 7–8%, up from prior 6–7%.
  • ↓Adjusted free cash flow declined to $4 M from $20 M, stressing liquidity.
Full analysis →
Insider Trades29 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Jun 15, 2026SellLIVNAhmet TezelChief Innovation Officer1,032$79.70$4.4B-5.36%+96.76%$82.3K-7.91%—Stalk
Mar 30, 2026SellLIVNAhmet TezelChief Innovation Officer1,186$61.27$4.4B-5.36%+96.76%$72.7K-2.97%—Stalk
Mar 30, 2026SellLIVNFranco PolettiPresident, Cardiopulmonary1,370$61.27$4.4B-5.36%+96.76%$83.9K-7.69%—Stalk
Mar 30, 2026SellLIVNNatalia KozminaChief Human Resources Officer1,374$61.27$4.4B-5.36%+96.76%$84.2K-3.55%—Stalk
Mar 30, 2026SellLIVNStephanie BoltonPresident, Global Epilepsy8,377$61.27$4.4B-5.36%+96.76%$513.3K-14.70%—Stalk
Mar 30, 2026SellLIVNVladimir MakatsariaChief Executive Officer11,159$61.27$4.4B-5.36%+96.76%$683.7K-6.49%—Stalk
Mar 30, 2026SellLIVNAlex ShvartsburgChief Financial Officer12,868$61.27$4.4B-5.36%+96.76%$788.4K-12.45%—Stalk
Mar 11, 2026BuyLIVNFranco PolettiPresident, Cardiopulmonary4,189$59.88$4.4B-5.36%+96.76%$250.8K+0.32%—Stalk
Dec 15, 2025SellLIVNFranco PolettiPresident, Cardiopulmonary416$63.06$4.4B-5.36%+96.76%$26.2K-4.49%—Stalk
Dec 15, 2025SellLIVNMichael Damon HutchinsonSVP, CLO and Company Secretary1,122$63.06$4.4B-5.36%+96.76%$70.8K-11.03%—Stalk
Sep 15, 2025SellLIVNFranco PolettiPresident, Cardiopulmonary277$55.43$4.4B-5.36%+96.76%$15.4K-2.64%—Stalk
Jun 15, 2025SellLIVNAhmet TezelChief Innovation Officer1,032$45.76$4.4B-5.36%+96.76%$47.2K-8.70%—Stalk
Mar 30, 2025SellLIVNFranco PolettiPresident, Cardiopulmonary542$39.13$4.4B-5.36%+96.76%$21.2K-1.23%—Stalk
Mar 30, 2025SellLIVNMichael Damon HutchinsonChief Legal Officer1,020$39.13$4.4B-5.36%+96.76%$39.9K-1.69%—Stalk
Mar 30, 2025SellLIVNStephanie BoltonPresident, Global Epilepsy2,835$39.13$4.4B-5.36%+96.76%$110.9K-4.82%—Stalk
Mar 30, 2025SellLIVNAlex ShvartsburgChief Financial Officer3,516$39.13$4.4B-5.36%+96.76%$137.6K-3.60%—Stalk
Mar 30, 2025SellLIVNVladimir MakatsariaChief Executive Officer5,046$39.13$4.4B-5.36%+96.76%$197.4K-2.30%—Stalk
Dec 15, 2024SellLIVNAlex ShvartsburgChief Financial Officer229$51.50$4.4B-5.36%+96.76%$11.8K-1.18%—Stalk
Dec 15, 2024SellLIVNFranco PolettiPresident, Cardiopulmonary416$51.50$4.4B-5.36%+96.76%$21.4K-4.84%—Stalk
Dec 15, 2024SellLIVNMichael Damon HutchinsonChief Legal Officer784$51.50$4.4B-5.36%+96.76%$40.4K-8.67%—Stalk
Jun 15, 2024SellLIVNAlex ShvartsburgCFO670$52.68$4.4B-5.36%+96.76%$35.3K-3.45%—Stalk
Mar 30, 2024SellLIVNMichael Damon HutchinsonChief Legal Officer542$55.94$4.4B-5.36%+96.76%$30.3K-1.45%—Stalk
Mar 30, 2024SellLIVNStephanie BoltonPresident, Global Epilepsy3,643$55.94$4.4B-5.36%+96.76%$203.8K-8.28%—Stalk
Mar 30, 2024SellLIVNTrui HebbelinckChief Human Resources Officer5,541$55.94$4.4B-5.36%+96.76%$310.0K-11.99%—Stalk
Mar 30, 2024SellLIVNAlex ShvartsburgCFO6,310$55.94$4.4B-5.36%+96.76%$353.0K-8.89%—Stalk
Feb 29, 2024SellLIVNWilliam A KozyChairman and CEO4,871$54.81$4.4B-5.36%+96.76%$267.0K-15.07%—Stalk
Dec 15, 2023SellLIVNAlex ShvartsburgCFO167$50.07$4.4B-5.36%+96.76%$8.4K-1.64%—Stalk
Dec 15, 2023SellLIVNMichael Damon HutchinsonChief Legal Officer904$50.07$4.4B-5.36%+96.76%$45.3K-10.03%—Stalk
Sep 15, 2023SellLIVNTrui HebbelinckChief Human Resources Officer207$56.80$4.4B-5.36%+96.76%$11.8K-2.67%—Stalk